VERA THERAPEUTICS INC. - CLASS A COMMON STOCK

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

22 11 2024 15:05:00 提供 Nasdaq GlobeNewswire

Vera Therapeutics Appoints Jason S. Carter as Chief Legal Officer

18 11 2024 07:00:00 提供 Nasdaq GlobeNewswire

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

11 11 2024 15:05:00 提供 Nasdaq GlobeNewswire

Vera Therapeutics Partners with University of Michigan on the NEPTUNE Match Project and PIONEER Study

11 11 2024 07:00:00 提供 Nasdaq GlobeNewswire

Vera Therapeutics to Participate at Upcoming Investor Conferences

08 11 2024 15:05:00 提供 Nasdaq GlobeNewswire

Vera Therapeutics to Participate at Upcoming Investor Conferences

08 11 2024 07:00:00 提供 Nasdaq GlobeNewswire

Vera Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results

07 11 2024 07:00:01 提供 Nasdaq GlobeNewswire

Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock

29 10 2024 19:22:02 提供 Nasdaq GlobeNewswire

Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock

28 10 2024 16:37:30 提供 Nasdaq GlobeNewswire

Vera Therapeutics Announces 96-week eGFR Stabilization in ORIGIN Phase 2b Study of Atacicept in IgAN in a Late-Breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024

26 10 2024 18:30:00 提供 Nasdaq GlobeNewswire

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 10 2024 15:05:00 提供 Nasdaq GlobeNewswire

Vera Therapeutics Announces Expanded Atacicept Development Program In Multiple Autoimmune Kidney Diseases

02 10 2024 05:30:00 提供 Nasdaq GlobeNewswire

Vera Therapeutics Announces Late-Breaking Oral Presentation of ORIGIN Phase 2b Long-term Results at the American Society of Nephrology Kidney Week 2024

02 10 2024 05:30:00 提供 Nasdaq GlobeNewswire

Vera Therapeutics to Host In-Person R&D Day in New York to Discuss Potential Indication Expansion for Atacicept on October 2, 2024

16 9 2024 07:00:00 提供 Nasdaq GlobeNewswire

Vera Therapeutics Completes Enrollment for Primary Endpoint in Pivotal Phase 3 ORIGIN 3 Trial of Atacicept in IgAN

12 9 2024 07:00:00 提供 Nasdaq GlobeNewswire

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

10 9 2024 15:05:00 提供 Nasdaq GlobeNewswire

Vera Therapeutics to Participate at September Investor Conferences

29 8 2024 07:00:00 提供 Nasdaq GlobeNewswire

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

09 8 2024 15:05:00 提供 Nasdaq GlobeNewswire

Vera Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results

08 8 2024 07:00:01 提供 Nasdaq GlobeNewswire

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 7 2024 15:30:00 提供 Nasdaq GlobeNewswire